Meta Biomed Co., Ltd. (KOSDAQ:059210)

Meta Biomed Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	99,381	94,036	83,101	68,942	58,780	44,998
Other Revenue	-0	-	-0	-0	-0	-
Revenue	99,381	94,036	83,101	68,942	58,780	44,998
Revenue Growth (YoY)	10.31%	13.16%	20.54%	17.29%	30.63%	-24.23%
Cost of Revenue	46,292	46,675	45,110	39,746	33,778	25,389
Gross Profit	53,089	47,361	37,990	29,196	25,003	19,608
Selling, General & Admin	24,992	23,143	21,651	18,682	15,455	13,359
Research & Development	4,037	5,140	4,538	4,343	3,339	2,227
Operating Expenses	30,994	30,139	27,388	23,831	19,741	17,094
Operating Income	22,095	17,222	10,602	5,365	5,261	2,514
Interest Expense	-3,775	-3,742	-2,315	-1,390	-1,145	-1,011
Interest & Investment Income	991.97	635.32	375.03	206.78	29.82	31.36
Earnings From Equity Investments	943.99	-	-	-	537.62	468.69
Currency Exchange Gain (Loss)	-389.98	3,453	232.84	-523.93	1,509	-1,236
Other Non Operating Income (Expenses)	-2,455	4,212	-861.26	-734.59	1,171	433.05
EBT Excluding Unusual Items	17,412	21,781	8,034	2,923	7,364	1,200
Gain (Loss) on Sale of Investments	1,084	1,530	773.17	426.74	-39.83	-335.36
Gain (Loss) on Sale of Assets	-68.69	-13.88	12.62	47.62	801.18	180.36
Asset Writedown	-	-	-1,015	-487.37	-541.23	-4,661
Pretax Income	18,427	23,297	7,805	2,910	7,584	-3,616
Income Tax Expense	990.92	1,146	-2,223	64.5	-1,938	-529.21
Earnings From Continuing Operations	17,436	22,150	10,027	2,846	9,521	-3,087
Earnings From Discontinued Operations	74.83	174.43	-211.99	754.18	140.51	-1,003
Net Income to Company	17,511	22,325	9,815	3,600	9,662	-4,090
Minority Interest in Earnings	82.55	77.62	265	-972.22	-140.45	-3.75
Net Income	17,593	22,402	10,080	2,628	9,522	-4,093
Net Income to Common	17,593	22,402	10,080	2,628	9,522	-4,093
Net Income Growth	18.86%	122.24%	283.61%	-72.40%	-	-
Shares Outstanding (Basic)	23	23	23	23	23	23
Shares Outstanding (Diluted)	27	27	23	23	23	23
Shares Change (YoY)	19.78%	18.55%	-0.06%	-0.07%	-0.61%	-1.08%
EPS (Basic)	760.01	979.63	440.75	114.82	415.77	-177.66
EPS (Diluted)	685.72	658.59	440.75	114.82	415.77	-177.66
EPS Growth	25.13%	49.43%	283.85%	-72.38%	-	-
Free Cash Flow	10,099	11,719	-1,271	-6,236	9,069	2,634
Free Cash Flow Per Share	368.64	432.22	-55.59	-272.48	396.00	114.32
Dividend Per Share	30.000	30.000	20.000	20.000	20.000	10.000
Dividend Growth	50.00%	50.00%	-	-	100.00%	-
Gross Margin	53.42%	50.36%	45.72%	42.35%	42.54%	43.58%
Operating Margin	22.23%	18.31%	12.76%	7.78%	8.95%	5.59%
Profit Margin	17.70%	23.82%	12.13%	3.81%	16.20%	-9.10%
Free Cash Flow Margin	10.16%	12.46%	-1.53%	-9.04%	15.43%	5.85%
EBITDA	27,263	22,203	14,825	9,225	8,832	6,455
EBITDA Margin	27.43%	23.61%	17.84%	13.38%	15.02%	14.35%
D&A For EBITDA	5,168	4,981	4,223	3,860	3,571	3,941
EBIT	22,095	17,222	10,602	5,365	5,261	2,514
EBIT Margin	22.23%	18.31%	12.76%	7.78%	8.95%	5.59%
Effective Tax Rate	5.38%	4.92%	-	2.22%	-	-
Advertising Expenses	-	298.35	151.08	230.86	245.85	141.51

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.